Anhui Huaren Health Pharmaceutical Co.,Ltd. has recently announced a plan to issue A-shares to specific investors in 2026, aiming to raise up to 709 million yuan. The funds are earmarked for a smart manufacturing and sorting center, pharmaceutical R&D, IT upgrades, and working capital. This marks the company’s first refinancing move since its ChiNext debut in March 2023.

However, the proposal comes amid several red flags: the company's previous IPO proceeds of 879 million yuan remain largely unspent, goodwill is high, institutional shareholders are rapidly exiting, and regulatory pressures on the pharmaceutical retail sector continue to tighten. This raises questions about the sustainability of Anhui Huaren Health’s aggressive expansion strategy.

IPO Funds Unspent, New $709M Private Placement Raises Goodwill Concerns

According to the announcement, the private placement aims to raise 709 million yuan (net of issuance costs), with the largest portion of 409 million yuan allocated to the smart manufacturing and sorting center. Another 108 million yuan is slated for R&D on high-end generics, standard generics, and Class 2 innovative drugs, while 43 million yuan is for IT infrastructure, and 150 million yuan for working capital.

A key concern is that the company has not yet fully used its IPO funds. Anhui Huaren Health raised net proceeds of 879 million yuan in its February 2023 IPO, which included 274 million yuan in over-allotment funds. As of June 30, 2026, only 90.71% (798 million yuan) had been utilized, with 93.369 million yuan still sitting in the designated account. Meanwhile, between 2024 and 2026, the company consistently used up to 600 million yuan of idle funds for cash management. By the end of the first quarter of 2026, its cash and financial assets totaled about 1 billion yuan, against short-term borrowings and current liabilities of 624 million yuan. Given the unspent IPO funds and ongoing cash management, the rationale for raising more capital, especially for working capital, is questionable.

In fact, Anhui Huaren Health has already shifted IPO funds originally intended for store network expansion to fund acquisitions. In 2024, it redirected 45 million yuan to acquire a stake in Zhoushan Liken Pharmacy. In May 2025, it announced a further reallocation of 131 million yuan from the store network project to acquire three pharmacy chains in Fujian and Zhejiang provinces. While this external growth strategy quickly scales up operations, it has led to integration challenges and a rising goodwill burden.

As IPO funds dwindle, the company urgently needs new financing to sustain its expansion pace, which appears to be the core driver of this private placement. The cost of rapid M&A is evident in Anhui Huaren Health’s surging goodwill. In 2024, it acquired Jiangsu Shenhua Pharmaceutical for 327 million yuan, entering the pharmaceutical manufacturing sector. Between late 2023 and 2024, it also acquired Zhoushan Liken and Anji Baixingyuan in Zhejiang, deepening its reach in the Yangtze River Delta. In 2025, a major acquisition year, it announced the purchase of three chains: Fujian Yangzu Huimin, Fujian Haihua Pharmaceutical, and Tonglu Yishengtang. Based on income method valuations, the appraisal premiums were 892.79% for Yangzu Huimin, 1,029.40% for Haihua Pharmaceutical, and a staggering 2,350.84% for Tonglu Yishengtang. Yet, the performance commitments tied to these high premiums are conservative. For example, Yangzu Huimin’s net profit commitments for 2025-2027 are only 13.6 million yuan, 14.28 million yuan, and 14.994 million yuan, respectively, implying an annual growth rate of just 5%.

As of March 31, 2026, Anhui Huaren Health’s goodwill stood at 1.282 billion yuan, up 29.75% year-on-year and representing about 23% of total assets. The risk of impairment is already materializing. Its 2025 annual report showed a goodwill impairment provision of over 72 million yuan, even as the industry remained stable and acquisitions were still within their performance commitment periods. As these commitments expire, if target companies’ profitability declines, the scale of goodwill impairments could expand significantly.

Policy Headwinds from Medicare, Centralized Procurement, and Institutional Investor Exits

Anhui Huaren Health’s decision to launch the private placement now is not only driven by internal funding needs but also by a broader transformation in the pharmaceutical retail sector. Multiple factors—including deepening Medicare reforms, expanded centralized drug procurement, online competition, and stricter regulation—are reshaping the industry. The company’s counter-cyclical expansion strategy could either be a chance to overtake rivals or a sign of over-optimism.

The pharmaceutical retail sector’s rapid growth over the past decade was largely fueled by the traffic benefits of Medicare-designated pharmacy status. However, this is fading fast. First, the reform of individual Medicare accounts has significantly reduced the amount credited to them, with contributions falling by 30% to 50% for many insured individuals since 2023. This directly cuts spending at pharmacies. Meanwhile, the rollout of outpatient co-payment policies at pharmacies has been uneven, with reimbursement rates often lower than those at primary care clinics and subject to high deductibles and limited coverage, failing to offset the account shrinkage.

Second, centralized procurement policies are extending to retail pharmacies, requiring them to match the winning prices. Average drug price cuts exceed 50%, with some dropping over 90%, making it difficult for pharmacies to profit from high-margin branded drugs. The margins on procured drugs are thin, causing disruption as pharmacies adjust their product mix.

Third, Medicare oversight is intensifying. Unannounced inspections have become routine, cracking down on practices like swapping drugs, using cards to buy non-medical items, and fraudulent claims. In 2023, 2.16 billion yuan was recovered nationwide, and enforcement has tightened further in 2025, with white list and blacklist systems for designated pharmacies increasing the cost of non-compliance.

Under these pressures, the industry’s average gross margin has been declining. Data shows that in 2025, the average gross margin of national pharmacies was 5 to 8 percentage points lower than in 2020, with some regions seeing even steeper drops. It remains to be seen whether Anhui Huaren Health can withstand this ongoing margin squeeze.

Additionally, since the lock-up period expired, multiple early institutional and industrial investors have been reducing their stakes. Alibaba Health, once the company’s second-largest shareholder with a strategic investment in 2018 and a peak holding of over 7%, executed a major sale in 2025, cashing out about 120 million yuan and reducing its stake to below 5%, freeing it from ongoing disclosure requirements. Saifu Investment’s affiliated funds have also been actively selling. In early 2026, a Saifu entity announced a plan to sell up to 8 million shares within three months, causing significant stock price volatility the next day. By the end of April 2026, Saifu had sold 4 million shares. Huatai Zijin’s Huatai Big Health No. 1 Fund has been even more aggressive. In 2023, it was the company’s fourth-largest shareholder, holding 20.95 million shares (5.24% of total equity). By 2025, its stake had fallen to 2.38 million shares (0.6%), and by the first quarter of 2026, it had completely exited the top ten shareholders list.